Tislelizumab for advanced solid tumors not responding to treatment
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a drug called tislelizumab (a type of immunotherapy) for people with advanced solid tumors that have stopped responding to standard treatments. The drug may help your immune system fight the cancer, but only if your tumor shows a specific genetic marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have advanced or metastatic cancer (cancer that has spread) that no longer responds to standard treatments.
- A recent tissue sample (biopsy) from the last 2 years must show a specific genetic marker that may predict response to the study drug.
- You must be in generally good health (able to perform daily activities).
- You have not been treated with immunotherapy (PD-1/PD-L1 or CTLA-4 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Hear when a new Refractory Solid Cancer Patients Unexposed to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.